Marcusson Consulting supplies the following services:

RNA therapeutics drug discovery

  • Design of RNA therapeutics (e.g. ASOs, siRNAs, mRNAs etc.)
  • Discovery research and early development plans
  • Identifying patient sub-populations in order to improve therapeutic efficacy of molecularly targeted drugs
  • Matching animal models to the precise intended patient population to maximize translatability of discovery research
  • Analysis of oncogenic pathways and target selection/validation
  • Biomarker strategy

Evaluation of Oncology or RNA therapeutic companies as investment opportunities

  • Evaluation of the company’s technology base
  • Analysis of strategic plans (e.g. targets, feasibility)
  • Determination of realistic time lines for early discovery through IND

Oligonucleotide therapeutics

  • Understanding of oligonucleotide PK properties
  • Selection of best drug delivery systems (e.g. lipids, nanoparticles, conjugates etc.)
  • Identification of proper biomarkers for the intended therapeutic target
  • Pinpointing the best way to identify PK/PD correlates

Biology and targeting of noncoding RNAs including microRNA and noncoding RNA

  • Advice on the complicated biology of microRNAs and other noncoding RNAs
  • Knowledge of phenotypic effects of major microRNAs
  • Bioinformatic services to understand genome-wide expression data